Kentaro Yonekura

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Youn H. Kim, M. Bagot, Lauren Pinter‐Brown et al. · The Lancet Oncology · 2018 · 645 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

Koji Izutsu, Shinichi Makita, Kisato Nosaka et al. · Blood · 2022 · 156 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Clinical significance of serum Th1‐, Th2‐ and regulatory T cells‐associated cytokines in adult T‐cell leukemia/lymphoma: High interleukin‐5 and ‐10 levels are significant unfavorable prognostic factors

Atsushi Inagaki, Takashi Ishida, Toshihiko Ishii et al. · International Journal of Cancer · 2006 · 82 citations · Full text

Life Sciences, Hematology, Immunology +17

Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: A blood eosinophilia is a significant unfavorable prognostic factor

Atae Utsunomiya, Takashi Ishida, Atsushi Inagaki et al. · Leukemia Research · 2006 · 70 citations

Medicine, Hematology, Oncology +17

Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T‐cell lymphoma

Hidetsugu Kawai, Kiyoshi Ando, Dai Maruyama et al. · Cancer Science · 2021 · 52 citations · Full text

Medicine, Oncology, Pharmacology +13